ABVC BioPharma Q3 revenue $389K, net loss narrows to $134K; first operational profit

ABVC BIOPHARMA, INC.

2024-Q3 EPS reported -$0.46 revenue$507,623

Revenue of $389,276 in Q3 2024 vs $15,884 in Q3 2023, a 2,350% increase.
Net loss narrowed to $134,272 from $3.37M; EPS improved to -$0.02 from -$0.82.
Cash balance grew to $137,344 vs $60,155 at year-end 2023.
Achieved first operational profit but higher interest from convertible debt kept EPS negative.
Licensing agreements could provide up to $292 million; $496K milestone cash received in 9 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.